“We have to wait for the analysis of the full data. What we know so far suggests that oral anticoagulation is not as effective as we hoped for in patients with AHRE”, explains Prof. Paulus Kirchhof, principal investigator of NOAH – AFNET 6.
The AFNET is conducting NOAH – AFNET 6 (Non-vitamin K antagonist Oral anticoagulants in patients with AHRE) since 2016 as an investigator-initiated trial in 18 European countries, financially supported by Daiichi Sankyo Europe and the German Centre for Cardiovascular Research (DZHK). Recently the target number of 2538 randomised and treated patients was reached. Early termination of the study means for the participants that they are advised to come timely to the study site for a final visit at which the intake of study medication ends.
More www.kompetenznetz-vorhofflimmern.de/en/
NOAH–AFNET 6 trial terminates ahead of time (NOAH AFNET 6 trial)